Application of chimeric antigen receptor modified mesenchymal stem cells in preparation of drugs for treating systemic lupus erythematosus
By expressing the chimeric antigen receptor CAR1 targeting B cells on mesenchymal stem cells and activating the JAK-STAT1 pathway, the individual response variability of MSCs therapy in SLE treatment and the risks of CAR-T therapy were addressed, achieving stable immunosuppressive effects, expanding the scope of application and improving safety.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES
- Filing Date
- 2025-01-16
- Publication Date
- 2026-07-17
AI Technical Summary
Existing MSCs therapies for the treatment of systemic lupus erythematosus (SLE) exhibit significant individual variability and are greatly influenced by the inflammatory environment. CAR-T therapy carries clinical risks and side effects, and the applicability of existing gene-modified MSCs therapies is limited.
By using chimeric antigen receptor-modified mesenchymal stem cells (CAR1-MSCs), the CD19 antigen targeting B cells is expressed on the surface of MSCs through genetic engineering and the JAK-STAT1 pathway is activated to achieve stable immunosuppressive function.
CAR1-MSCs exhibit stable B-cell-specific immunosuppressive capacity in vitro, reducing the impact of T-cell activation, expanding the applicability of MSCs therapy, and improving the efficacy and safety of SLE treatment.
Smart Images
Figure CN122399015A_ABST